INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of terlipressin, however, is hindered by the pau...

Full description

Bibliographic Details
Main Authors: Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Contemporary Clinical Trials Communications
Subjects:
Decompensated cirrhosis
Portal hypertension
Ascites
Hepatorenal syndrome
Liver transplant
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865423001576

Similar Items

Similar Items